Rivastigmine Multi-Day Transdermal Patch (Rivastigmine MD) is a twice-weekly innovative patch formulation of Rivastigmine for the treatment of mild to moderate dementia associated with Alzheimer ...

Luye Pharma Group announced that its partner Towa Pharmaceutical Co., Ltd. (Towa) has filed a New Drug Application (NDA) to the Ministry of Health, Labour and Welfare (MHLW) in Japan for the ...

Rivastigmine Transdermal System is available as 4.6mg/24hrs, 9.5mg/24hrs, and 13.3mg/24hrs strengths. For more information call (973) 796-3400 or visit Alvogen.com . Picked For You ...

September 4, 2012 — The US Food and Drug Administration (FDA) has approved a 13.3 mg/24 hour dosage strength of the rivastigmine transdermal system (Exelon, Novartis) for patients with mild to ...

In elderly patients with cognitive dysfunction undergoing surgery for hip fracture, perioperative application of the rivastigmine patch reduced incidence postoperative delirium. VANCOUVER, BC—In ...

In a study aimed at finding answers for those with advanced Alzheimer’s disease, researchers at Saint Louis University are testing a new, higher dose of the Exelon (rivastigmine) patch to learn ...

Luye Pharma Group today announced that marketing approval for its innovative formulation Rivastigmine Twice Weekly Transdermal Patch has been granted by the Japanese Ministry of Health, Labour and ...

Luye Pharma Group today announced that marketing approval for its innovative formulation Rivastigmine Twice Weekly Transdermal Patch has been granted by the Japanese Ministry of Health, Labour and ...